Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Soft inquiry prequalifications for credit cards let you shop offers without hurting your score. This intro covers what to expect and next steps.
11,308 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
A new 530A account aims to boost child wealth, but uptake is tepid as July 4 launches draws near. Experts warn billio...
VYM has posted strong long-term gains, delivering around 200% over 10 years. Yet its income yield lags behind more in...
Demi Moore reportedly lands a top per-episode rate, highlighting how big contracts affect seasons, taxes, and long-te...
Valr, Africa’s largest crypto exchange by trade volume, expands its derivatives with Hyperliquid, adding 200+ cross-a...
Ripple (XRP) is facing a critical test near the $1 threshold as ETF flows turn mixed and on-chain signals flicker. Tr...
July 2026 offers a compelling setup for patient investors. Here’s my top-ranked stock for July, why it stands out, an...
Two healthcare ETFs offer very different paths for investors: a broad, low-cost core and a concentrated pharmaceutica...
As chatter swirls about SpaceX joining the NASDAQ-100, savvy investors are asking for a safer, higher-conviction pick...
Investors are weighing Hut 8 and Riot Platforms as data-center developers expanding beyond Bitcoin mining. This guide...
Two traders file a civil suit accusing Polymarket of misresolving a Strategy bitcoin sale market after a late May dis...
For dividend kings long-term investors, a disciplined, income-forward approach can power wealth over two decades. Thi...